AtaiBeckley

Srinivas Rao is Co-Founder and CEO of AtaiBeckley and previously co-founded atai Life Sciences, where he served as Chief Scientific Officer for five years before becoming Co-Chief Executive in 2023. He has over two decades of experience in the pharmaceutical industry, holding scientific, medical, and executive roles at companies ranging from venture-backed startups to publicly traded firms. He earned his medical degree from Yale School of Medicine and holds a Ph.D. in Neurobiology and a Master of Science in Electrical Engineering from Yale.

Ryan Barrett is Chief Legal and Business Officer at atai Life Sciences, a role he assumed in 2025 after serving as General Counsel since joining in 2020. He has spent over a decade on the executive teams of public and private biotechnology companies, overseeing legal, corporate development, and intellectual property functions. He holds a JD from Case Western Reserve University School of Law and B.S. in biochemistry and B.A. in Italian from Trinity College, and is admitted to the Massachusetts bar.

Kevin Craig became Chief Medical Officer of atai Life Sciences in 2025, having joined in 2021 as Vice President and later Senior Vice President of Clinical Development, where he oversees clinical development, regulatory affairs, drug safety, biostatistics, and global clinical operations. He has more than 20 years of clinical experience with a focus on neuroscience pipelines, and previously held a faculty appointment at the University of Cambridge's Behavioral and Clinical Neuroscience Institute and worked at P1vital on imaging and cognitive biomarkers for early-phase psychiatry trials. He earned his medical degree from the University of Witwatersrand and an MPhil in Medical Science from the University of Cambridge, and is a member of the Royal College of Psychiatrists with accreditation in addiction and adult psychiatry.

Rob Hershberg is Co-Founder, President, CEO and board chairman of HilleVax, and a Venture Partner with Frazier Healthcare Partners, where he has worked with the firm and its portfolio companies for 14 years. He previously co-founded and led VentiRx Pharmaceuticals, and held senior roles at Celgene (including Chief Scientific Officer and Head of Business Development & Global Alliances), Dendreon, and Corixa. He earned his undergraduate and medical degrees at UCLA and a Ph.D. from the Salk Institute, and previously served as an assistant professor at Harvard Medical School.